Entrada Therapeutics Total Current Liabilities

The latest total current liabilities for TRDA is $21M as of June 2026. That compares with $20M in the prior-year period — up 7.9% year over year. Investors often review this figure alongside Entrada Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRDA's total current liabilities moved from $20M to $21M — a 7.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Entrada Therapeutics's operating scale or balance-sheet position.

A total current liabilities figure of $21M for TRDA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TRDA's total current liabilities ($21M), review year-over-year change from $20M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.